As the dose of Sutro Biopharma’s ovarian cancer drug, STRO-002, increased in an ongoing Phase I dose-escalation trial, meaningful clinical benefit rates have also increased, the company announced on Thursday. STRO-002 is a folate receptor alpha (FolRα) targeting antibody-drug conjugate (ADC) for the treatment of ovarian cancer, a disease that is highly treatable if caught early, […]

Just a few months after its last interim readout, Sutro Biopharma $STRO is sharing more Phase I data in a small, single-arm trial for its ovarian cancer program. The San Francisco-based biotech announced Thursday afternoon that patients with heavy previous treatment continued to see improvements as they remained on the drug, with one individual achieving […]

Sutro Biopharma’s lead antibody-drug conjugate beat back ovarian cancer in a small phase 1 study, shrinking tumors in 13% of patients who had tried a median of six other treatments. The study tested various doses of the treatment, STRO-002, an ADC targeting folate receptor alpha (FolRα), in 39 patients who had received multiple kinds of […]